Abstract
Sanofi Pasteur and MedImmune, the biologics arm of AstraZeneca, have agreed to develop MED18897, a monoclonal antibody, for the prevention of lower respiratory tract illness caused by respiratory syncytial virus. MED18897 is currently in a Phase II clinical trial involving infants ineligible for Synagis, the current standard of care. Sanofi Pasteur will make an up-front payment of $127 million to MedImmune and milestone payments of up to $523 million.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
